Silvant Capital Management LLC Sells 1,142 Shares of Axon Enterprise, Inc $AXON

Silvant Capital Management LLC lowered its position in Axon Enterprise, Inc (NASDAQ:AXON) by 8.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,074 shares of the biotechnology company’s stock after selling 1,142 shares during the quarter. Silvant Capital Management LLC’s holdings in Axon Enterprise were worth $8,665,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Advisory Services Network LLC lifted its stake in Axon Enterprise by 11.1% in the 3rd quarter. Advisory Services Network LLC now owns 3,670 shares of the biotechnology company’s stock valued at $2,634,000 after purchasing an additional 366 shares during the last quarter. Harvest Investment Services LLC increased its position in Axon Enterprise by 166.5% during the third quarter. Harvest Investment Services LLC now owns 8,452 shares of the biotechnology company’s stock worth $6,065,000 after buying an additional 5,280 shares during the last quarter. Synergy Financial Group LTD raised its stake in Axon Enterprise by 1.4% in the third quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock valued at $996,000 after buying an additional 19 shares during the period. Castleark Management LLC raised its stake in Axon Enterprise by 1,751.3% in the third quarter. Castleark Management LLC now owns 9,627 shares of the biotechnology company’s stock valued at $6,909,000 after buying an additional 9,107 shares during the period. Finally, CANADA LIFE ASSURANCE Co lifted its position in shares of Axon Enterprise by 28.3% in the third quarter. CANADA LIFE ASSURANCE Co now owns 111,006 shares of the biotechnology company’s stock valued at $79,451,000 after buying an additional 24,503 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $506.57 on Wednesday. The stock has a 50 day simple moving average of $526.65 and a 200 day simple moving average of $604.44. The stock has a market cap of $40.73 billion, a P/E ratio of 333.27, a PEG ratio of 10.45 and a beta of 1.46. Axon Enterprise, Inc has a 1-year low of $396.41 and a 1-year high of $885.91. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.53.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.55. The firm had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The company’s revenue for the quarter was up 38.5% on a year-over-year basis. During the same period in the prior year, the firm posted $2.08 EPS. Research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, CAO Jennifer H. Mak sold 1,500 shares of Axon Enterprise stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $573.45, for a total value of $860,175.00. Following the completion of the sale, the chief accounting officer owned 12,240 shares in the company, valued at $7,019,028. The trade was a 10.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Isaiah Fields sold 2,000 shares of the business’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the completion of the sale, the insider directly owned 55,588 shares of the company’s stock, valued at $29,740,135.88. This represents a 3.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 24,634 shares of company stock worth $13,803,095. Corporate insiders own 5.70% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on AXON. Barclays decreased their target price on Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. William Blair reaffirmed an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, February 3rd. Royal Bank Of Canada reduced their price objective on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a research report on Wednesday, February 25th. Citigroup reissued a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, February 25th. Finally, Wall Street Zen upgraded shares of Axon Enterprise from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $762.93.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.